ArticleActa pharmacologica Sinica2021
Fibronectin type III domain-containing 5 in cardiovascular and metabolic diseases: a promising biomarker and therapeutic target.
Article in Acta pharmacologica Sinica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 29 citations in OpenAlex.
- Irisin ameliorates obesity and insulin resistance via adipose tissue IL-33 and regulatory T cells.Nature metabolism · 2026Article
- Pyroptosis of Vascular Smooth Muscle Cells as a Potential New Target for Preventing Vascular Diseases.Cardiovascular drugs and therapy · 2025Review
- FNDC5 and ACOX1 as Biomarkers of Peroxisomal Activity with Contrast Outcomes in Colon Adenocarcinoma.Biological procedures online · 2025Article
- FNDC4 Prevents Aging-Related Cardiac Dysfunction: By Restoring AMPKα/PPARα-Dependent Mitochondrial Function.JACC. Basic to translational science · 2025Article
- FNDC4 alleviates cardiac ischemia/reperfusion injury through facilitating HIF1α-dependent cardiomyocyte survival and angiogenesis in male mice.Nature communications · 2024Article
- Suspension electrospinning of decellularized extracellular matrix: A new method to preserve bioactivity.Bioactive materials · 2024Article
- Trajectory of Irisin as a Predictor of Kidney-Related Outcomes in Patients with Asymptomatic Heart Failure.Biomedicines · 2024Article
- Exploration of the Potential Biomarker FNDC5 for Discriminating Heart Failure in Patients with Coronary Atherosclerosis.Journal of cardiovascular translational research · 2024Article
- The Role and Potential Mechanisms of Rehabilitation Exercise Improving Cardiac Remodeling.Journal of cardiovascular translational research · 2024Review
- The Role of FNDC4 in Inflammation and Metabolism for Various Diseases.Aging and disease · 2024Review
- The Role of the Myokine Irisin in the Protection and Carcinogenesis of the Gastrointestinal Tract.Antioxidants (Basel, Switzerland) · 2024Review
- Irisin, an Effective Treatment for Cardiovascular Diseases?Journal of cardiovascular development and disease · 2022Review
- Fibronectin type III domain-containing 5 improves aging-related cardiac dysfunction in mice.Aging cell · 2022Article
- MicroRNA-665-3p exacerbates nonalcoholic fatty liver disease in mice.Bioengineered · 2022Article
- Serum Levels of Irisin Predict Cumulative Clinical Outcomes in Heart Failure Patients With Type 2 Diabetes Mellitus.Frontiers in physiology · 2022Article
- Irisin as a Novel Biomarker of Subclinical Atherosclerosis, Cardiovascular Risk and Severe Disease in Axial Spondyloarthritis.Frontiers in immunology · 2022Article
- Irisin is an Effector Molecule in Exercise Rehabilitation Following Myocardial Infarction (Review).Frontiers in physiology · 2022Review
- HFpEF and Atrial Fibrillation: The Enigmatic Interplay of Dysmetabolism, Biomarkers, and Vascular Endothelial Dysfunction.Disease markers · 2022Article
- Osteocrin, a novel myokine, prevents diabetic cardiomyopathy via restoring proteasomal activity.Cell death & disease · 2021Article
- Irisin as a Potential Biomarker Associated with Myocardial Injuries in Patients with Severe Hypothyroidism.International journal of endocrinology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular and metabolic diseases are the leading causes of death and disability worldwide and impose a tremendous socioeconomic burden on individuals as well as the healthcare system. Fibronectin type III domain-containing 5 (FNDC5) is a widely distributed transmembrane glycoprotein that can be proteolytically cleaved and secreted as irisin to regulate glycolipid metabolism and cardiovascular homeostasis. In this review, we present the current knowledge on the predictive and therapeutic role of FNDC5 in a variety of cardiovascular and metabolic diseases, such as hypertension, atherosclerosis, ischemic heart disease, arrhythmia, metabolic cardiomyopathy, cardiac remodeling, heart failure, diabetes mellitus, and obesity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.